AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
estradiol valerate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| estrogens | 1064 | 979-32-8 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BA (Bioavailability) | 3 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| S (Water solubility) | 0.01 mg/mL | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 4.436 | Moderate | 0.65 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 0.543 | Moderate | 0.65 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 31.842 | 10^-6 cm/s | Moderate | 0.65 |
| dh-clint | Dog hepatocyte intrinsic clearance | 83.946 | uL/min/10^6 cells | Moderate | 0.65 |
| dppb | Dog plasma protein binding (% unbound) | 0.440 | % | Moderate | 0.65 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 0.880 | % | Moderate | 0.65 |
| herg | hERG pIC50 | 4.944 | pIC50 | Moderate | 0.65 |
| hh-clint | Human hepatocyte intrinsic clearance | 363.078 | uL/min/10^6 cells | Moderate | 0.65 |
| hlm-clint | Human liver microsomal intrinsic clearance | 157.036 | uL/min/mg protein | Moderate | 0.65 |
| hppb | Human plasma protein binding (% unbound) | 0.530 | % | Moderate | 0.65 |
| kinase-safety-class | ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,DYRK1B,EIF2AK3,ERBB2,GRK2,ITK,MAP2K6,MAP3K7,MAPK10,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIK3CG,PIM2,PRKDC,STK33,TEK,TGFBR1 | 29 | |||
| kinase-selectivity-class | EIF2AK3,GRK2 | 2 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 0.310 | Moderate | 0.65 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 557.186 | Moderate | 0.65 | |
| mppb | Mouse plasma protein binding (% unbound) | 0.730 | Moderate | 0.65 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 0.571 | Moderate | 0.65 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 1.620 | % | Moderate | 0.65 |
| rh-clint | Rat hepatocyte intrinsic clearance | 352.371 | uL/min/10^6 cells | Moderate | 0.65 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 8.870 | % | Moderate | 0.65 |
| rppb | Rat plasma protein binding (% unbound) | 0.600 | % | Moderate | 0.65 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 4.036 | uM | Moderate | 0.65 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| July 15, 1954 | FDA | PAR STERILE PRODUCTS |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Ovarian hyperstimulation syndrome | 126.10 | 36.31 | 28 | 1756 | 5834 | 90620829 |
| Vestibular migraine | 66.12 | 36.31 | 10 | 1774 | 242 | 90626421 |
| Endometrial cancer | 54.83 | 36.31 | 13 | 1771 | 3599 | 90623064 |
| Therapeutic response changed | 49.61 | 36.31 | 10 | 1774 | 1307 | 90625356 |
| Migraine | 49.49 | 36.31 | 36 | 1748 | 190356 | 90436307 |
| Ear congestion | 45.09 | 36.31 | 11 | 1773 | 3431 | 90623232 |
| Multiple lentigines syndrome | 44.90 | 36.31 | 7 | 1777 | 208 | 90626455 |
| Diabetic retinal oedema | 40.18 | 36.31 | 7 | 1777 | 415 | 90626248 |
| Bipolar disorder | 38.82 | 36.31 | 12 | 1772 | 8973 | 90617690 |
| Cataract subcapsular | 36.34 | 36.31 | 7 | 1777 | 724 | 90625939 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Ovarian hyperstimulation syndrome | 135.58 | 36.63 | 28 | 1668 | 5332 | 110582271 |
| Migraine | 50.82 | 36.63 | 32 | 1664 | 171620 | 110415983 |
| Ear congestion | 47.13 | 36.63 | 11 | 1685 | 3654 | 110583949 |
| Multiple lentigines syndrome | 45.42 | 36.63 | 7 | 1689 | 249 | 110587354 |
| Diabetic retinal oedema | 41.57 | 36.63 | 7 | 1689 | 437 | 110587166 |
| Vestibular migraine | 40.15 | 36.63 | 6 | 1690 | 173 | 110587430 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| FDA CS | M0447348 | Estradiol Congeners |
| FDA MoA | N0000000100 | Estrogen Receptor Agonists |
| MeSH PA | D004967 | Estrogens |
| MeSH PA | D006728 | Hormones |
| FDA EPC | N0000175825 | Estrogen |
| CHEBI has role | CHEBI:50114 | estrogen |
| CHEBI has role | CHEBI:77746 | human metabolite |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Contraception | indication | 13197004 | |
| Female hypogonadism syndrome | indication | 16041008 | |
| Primary ovarian failure | indication | 65846009 | |
| Menopausal flushing | indication | 198436008 | |
| Advanced Prostatic Carcinoma | indication | ||
| Metastatic Prostate Carcinoma | indication | ||
| Polycystic ovaries | off-label use | 69878008 | |
| Hyperlipoproteinemia | contraindication | 3744001 | DOID:1168 |
| Gynecomastia | contraindication | 4754008 | DOID:12698 |
| Hypocalcemia | contraindication | 5291005 | |
| Hypercholesterolemia | contraindication | 13644009 | |
| Myocardial infarction | contraindication | 22298006 | DOID:5844 |
| Diplopia | contraindication | 24982008 | |
| Retinal hemorrhage | contraindication | 28998008 | |
| Depressive disorder | contraindication | 35489007 | |
| Chloasma | contraindication | 36209000 | |
| Migraine | contraindication | 37796009 | DOID:6364 |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Disorder of gallbladder | contraindication | 39621005 | DOID:0060262 |
| Hypothyroidism | contraindication | 40930008 | DOID:1459 |
| Body fluid retention | contraindication | 43498006 | |
| Thrombosis of retinal vein | contraindication | 46085004 | |
| Humoral hypercalcemia of malignancy | contraindication | 47709007 | |
| Chronic heart failure | contraindication | 48447003 | |
| Dementia | contraindication | 52448006 | |
| Hepatic porphyria | contraindication | 55056006 | DOID:3133 |
| Systemic lupus erythematosus | contraindication | 55464009 | DOID:9074 |
| Hyperlipidemia | contraindication | 55822004 | DOID:1168 |
| Heart disease | contraindication | 56265001 | DOID:114 |
| Thrombophlebitis | contraindication | 64156001 | DOID:3875 |
| Intermenstrual bleeding - irregular | contraindication | 64996003 | |
| Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
| Sleep apnea | contraindication | 73430006 | DOID:0050847 |
| Epilepsy | contraindication | 84757009 | DOID:1826 |
| Breast lump | contraindication | 89164003 | |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Uterine leiomyoma | contraindication | 95315005 | DOID:13223 |
| Neoplasm of prostate | contraindication | 126906006 | DOID:10283 |
| Deep venous thrombosis | contraindication | 128053003 | |
| Seizure disorder | contraindication | 128613002 | |
| Endometriosis | contraindication | 129103003 | |
| Bed-ridden | contraindication | 160685001 | |
| Mammography abnormal | contraindication | 168750009 | |
| Asthma | contraindication | 195967001 | DOID:2841 |
| Cerebrovascular accident | contraindication | 230690007 | |
| Pulmonary thromboembolism | contraindication | 233935004 | |
| Thrombophilia | contraindication | 234467004 | DOID:2452 |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Endometrial carcinoma | contraindication | 254878006 | DOID:2871 |
| Benign prostatic hyperplasia | contraindication | 266569009 | |
| Edema | contraindication | 267038008 | |
| Chorea | contraindication | 271700006 | |
| Pregnancy, function | contraindication | 289908002 | |
| Hypertriglyceridemia | contraindication | 302870006 | |
| Functional visual loss | contraindication | 313165001 | |
| Malignant tumor of ovary | contraindication | 363443007 | DOID:2394 |
| Thromboembolic disorder | contraindication | 371039008 | |
| Cardiovascular event risk | contraindication | 395112001 | |
| Breastfeeding (mother) | contraindication | 413712001 | |
| Chronic lung disease | contraindication | 413839001 | |
| Disorder of coronary artery | contraindication | 414024009 | |
| Obesity | contraindication | 414916001 | DOID:9970 |
| Estrogen receptor positive tumor | contraindication | 416053008 | |
| Porphyria | contraindication | 418470004 | |
| Optic disc edema | contraindication | 423341008 | DOID:146 |
| Family history of malignant neoplasm of breast | contraindication | 429740004 | |
| Hypertensive urgency | contraindication | 443482000 | |
| Carcinoma of female breast | contraindication | 447782002 | |
| Smokes tobacco daily | contraindication | 449868002 | |
| Breast Carcinoma in Males | contraindication |
🐶 Veterinary Drug Use
| Species | Use | Relation |
|---|---|---|
| Cattle | To increase rate of weight gain | Indication |
| Cattle | To improve feed efficiency | Indication |
| Cattle | Synchronization of estrus/ovulation | Indication |
🐶 Veterinary products
| Product | Applicant | Ingredients |
|---|---|---|
| Syncro-Mate-B | Boehringer lngelheim Animal Health USA Inc. | 2 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 11.13 | acidic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| N/A,2MG,3MG,N/A,N/A;3MG,2MG,2MG,1MG,N/A | NATAZIA | BAYER HLTHCARE | N022252 | May 6, 2010 | RX | TABLET | ORAL | 8071577 | May 13, 2026 | PREVENTION OF PREGNANCY |
| N/A,2MG,3MG,N/A,N/A;3MG,2MG,2MG,1MG,N/A | NATAZIA | BAYER HLTHCARE | N022252 | May 6, 2010 | RX | TABLET | ORAL | 8153616 | Jan. 30, 2028 | TREATMENT OF HEAVY MENSTRUAL BLEEDING IN WOMEN WITHOUT ORGANIC PATHOLOGY WHO CHOOSE TO USE AN ORAL CONTRACEPTIVE AS THEIR METHOD OF CONTRACEPTION |
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Estrogen receptor | Nuclear hormone receptor | AGONIST | CHEMBL | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4017607 | VUID |
| N0000179123 | NUI |
| D01413 | KEGG_DRUG |
| 4017607 | VANDF |
| 4017609 | VANDF |
| 4021205 | VANDF |
| C0059623 | UMLSCUI |
| CHEBI:31561 | CHEBI |
| EST | PDB_CHEM_ID |
| CHEMBL1511 | ChEMBL_ID |
| DB13956 | DRUGBANK_ID |
| D004958 | MESH_DESCRIPTOR_UI |
| 13791 | PUBCHEM_CID |
| 7655 | IUPHAR_LIGAND_ID |
| 3921 | INN_ID |
| OKG364O896 | UNII |
| DB00783 | DRUGBANK_ID |
| 24395 | RXNORM |
| 4684 | MMSL |
| 4686 | MMSL |
| 6157 | MMSL |
| 6947 | MMSL |
| 73244 | MMSL |
| 756 | MMSL |
| 8602 | MMSL |
| d00537 | MMSL |
| 001265 | NDDF |
| 001269 | NDDF |
| 126172005 | SNOMEDCT_US |
| 12839006 | SNOMEDCT_US |
| 96350008 | SNOMEDCT_US |
| C0014912 | UMLSCUI |
| 5757 | PUBCHEM_CID |
| 406 | INN_ID |
| CHEBI:16469 | CHEBI |
| OKG364O896 | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Estradiol Valerate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9289 | INJECTION | 10 mg | INTRAMUSCULAR | ANDA | 15 sections |
| Estradiol Valerate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9290 | INJECTION | 20 mg | INTRAMUSCULAR | ANDA | 15 sections |
| Estradiol Valerate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9291 | INJECTION | 40 mg | INTRAMUSCULAR | ANDA | 15 sections |
| ESTRADIOL VALERATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0517-0420 | INJECTION, SOLUTION | 20 mg | INTRAMUSCULAR | ANDA | 26 sections |
| ESTRADIOL VALERATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0517-0440 | INJECTION, SOLUTION | 40 mg | INTRAMUSCULAR | ANDA | 26 sections |
| Delestrogen | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42023-110 | INJECTION | 10 mg | INTRAMUSCULAR | NDA | 27 sections |
| Delestrogen | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42023-111 | INJECTION | 20 mg | INTRAMUSCULAR | NDA | 27 sections |
| Estradiol valerate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70700-273 | INJECTION | 10 mg | INTRAMUSCULAR | ANDA | 27 sections |
| Estradiol valerate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70700-274 | INJECTION | 20 mg | INTRAMUSCULAR | ANDA | 27 sections |
| Estradiol valerate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70700-275 | INJECTION | 40 mg | INTRAMUSCULAR | ANDA | 27 sections |